Ascentage Pharma Group International (HKG:6855) presented 17 clinical updates from core assets at the 31st Congress of the European Hematology Association, including eight poster presentations, according to a Monday Hong Kong bourse filing.
The presentations included data from ongoing clinical studies of olverembatinib and lisaftoclax at the conference held in Stockholm, Sweden, from June 11 to June 14.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments